You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

November 12, 2012

Food Health Claims: Challenges for ASEAN Manufacturers

Informed Counsel

Within the food industry, all eyes are currently turned toward the European Union, because after December 14, 2012, new limitations will be introduced for acceptable health claims on food products.

Regulation No. 1924/2006 of the European Parliament and of the Council of December 20, 2006, on Nutrition and Health Claims Made on Foods (the Regulation) has changed the scope of the interpretation of health claims in the European Union. Initially, each country was entitled to have its own set of acceptable claims, but growing inconsistencies between countries made it difficult for manufacturers to sell their products.

European Regulation

In an attempt to harmonize the rules, the Regulation was adopted. It defined health claims as “any claim that states, suggests, or implies that a relationship exists between a food category, a food or one of its constituents and health” (Article 2 Definition 5). Such claims should not:

  • “Be false, ambiguous, or misleading.
  • Give rise to doubt about the safety and/or the nutritional adequacy of other foods.
  • Encourage or condone excess consumption of food.
  • State, suggest, or imply that a balanced and varied diet cannot provide the appropriate quantities of nutrients in general. . . .
  • Refer to changes in bodily functions which could give rise to or exploit fear in the consumer . . .”

As these restrictions are common in most countries in the world, they are not the reason why companies have raised concerns about this Regulation. The key issue is that the Regulation has provided specific conditions with regard to health claims applicable to products launched in Europe. For example, health claims will only be permitted if certain information is included in the labeling, presentation, or advertising, such as “a statement indicating the importance of a varied and balanced diet and healthy lifestyle” or “the quantity of the food and pattern of consumption required to obtain the claimed beneficial effect.”

The Regulation has set up a process by which companies are able to submit their proposed health claims for approval by the Commission. However, companies must submit generally accepted scientific evidence and ensure that the claim can be well understood by the average consumer. Of the 44,000 claims submitted, only 222 had been approved as of May 2012 according to Commission Regulation No. 432/2012, which established a list of permitted health claims made on foods, except for those claims referring to the reduction of disease or disease risk and to children’s development and health.

Surprisingly, some claims that were widely used in the past and approved by several national health agencies have been rejected, such as claims regarding prebiotics and probiotics products. The arguments raised by the Commission were that the scientific evidence provided by the submitting companies was not sufficient for this type of product. The main industries affected are currently raising their concerns with the Commission.

ASEAN Perspective

For companies set up within ASEAN, implementation of the Regulation will have a significant impact. Although most countries follow Codex Alimentarius and its Guidelines for use of Nutrition and Health Claims, discrepancies still exist between member countries as ASEAN has not yet implemented harmonized legislation on this particular topic. For example, a Malaysian company planning to sell its products in Thailand, Singapore, and the EU would face three different sets of requirements as some countries have even implemented a positive list of nutrition function claims. In another example, Thailand would not accept other function claims, contrary to Malaysia and Singapore, while the Singaporean authorities would authorize a disease risk reduction claim which would not be admissible in Malaysia or in Thailand.

Focusing on the examples of Thailand, Malaysia, and Singapore helps to highlight the differences among the interpretations of health claims in ASEAN, and thus the difficulties encountered by ASEAN companies to sell their products both within the region and overseas.

Thailand Experience

In Thailand, health claims are not described as clearly in legal terms compared to the EU, and interpretation is generally on a case-by-case basis. Section 40 of the Food Act refers indirectly to heath claims and states that “no one shall advertise the benefits, qualities, or efficacies of foods which are false or which are misleading, without getting prior approval from the Thai Food and Drug Administration (FDA).” The Notices of the FDA regarding “Bases on Food Advertisement” provide the requirements for food advertisements and for some specific food categories. However, only nutrition claims have specific acceptable guidelines in place set up by the Thai FDA (Notification of the Ministry of Public Health (MoPH) No. 182 of 1998 re: Nutrition Labeling).

An order of the Thai FDA No. 403/2551 (2008), “Consideration for Granting Permission to Make Health Claims for Probiotics in Food Products,” states that health claims are authorized for such products if they are backed with scientific evidence sufficient for the permission to use these types of claims. For other products, such as weight control products and other products falling into the Specially Controlled Food category, the process is similar, but might be more cumbersome.

Additionally, the first regulation specially targeting health claims has recently been implemented, and health claims for probiotics were clarified in the Notification of the MoPH regarding “Use of Probiotics in Food” dated June 27, 2011. A health claim means “a displaying of a picture, photograph, invented mark, mark, trademark, or any statement on the label which is related to the food, food components, or nutrients concerned with health, either directly or indirectly.”

Thus, it is interesting to observe that Thailand currently has, in practice, a recognized, strict approach toward health claims on food products. But contrary to the EU, Thailand still accepts most health claims for probiotic products if they are supported by scientific journals. Although a draft of the Notification on the Advertisement of Food will soon be published in the Government Gazette, there does not yet seem to be a move toward narrowing the types of claims  acceptable for food products. A notification regarding “Health Claims and Warnings” and an announcement regarding “Scientific Substantiation of Health Claims” are also in the early stages of the drafting process.

Malaysia Experience

The Malaysian Food Act of 1983, supported by the Food Regulation of 1985, amended in 2005 to encompass health and nutrition claims, is the main source of legislation in Malaysia covering health claims. Within ASEAN, Malaysia is the only country that makes nutrition labeling a requirement. A Guide to Nutrition Labeling and Claims has also been issued to assist companies in their advertisement process in Malaysia. Malaysia follows the Codex Alimentarius Guidelines for Use of Nutrition and Health Claims more closely than many other countries.

As in most ASEAN countries, nutrient claims and, more specifically, content claims, comparative claims, and nutrient function claims, are acceptable. There are no specific regulations on prebiotics and probiotics in Malaysia. Ingredients are permitted for use in health supplements and conventional food, but approval is required beforehand. Thus, prebiotics and probiotics claims are acceptable if such claims fall into the authorized claims by the Ministry of Health (e.g., “Bifidobacteria lactis helps foster a beneficial intestinal environment and may help to reduce the incidence of diarrhea”). The requirements for submitting a claim involve submitting sufficient scientific evidence (which includes five clinical trial approvals from other recognized countries), as well as ensuring that the claim is comprehensible for consumers.

Singapore Experience

The Singapore Food Regulations, supported by the Guide to Food Labeling and Advertisements, implement the scope of acceptability of health claims in Singapore. Under article 9 of the Food Regulations, false or misleading statements, words, brands, pictures, or marks purporting to indicate the nature, stability, quantity, strength, purity, composition, weight, origin, age, effects, or proportion of the food or any ingredients are not allowed to be used on food labels and advertisements, unless otherwise specified. Singapore also prohibits the use of:

  • Claims for therapeutic or prophylactic action.
  • Claims which could be interpreted as advice of a medical nature from any person.
  • Claims that a food will prevent, alleviate, or cure any disease or condition affecting the human body.
  • Claims that health or an improved physical condition may be achieved by consuming any food.

One particularity of Singapore is that risk-related claims are acceptable; similarly, in the EU, a list of acceptable nutrient function claims has been implemented. In order to obtain approval, a company would have to establish, among other requirements, that essential nutrients with established recommended intakes are of nutritional importance, and that the claim is sufficiently generally accepted by the scientific community and is understandable to consumers.

The Guide to Food Labeling and Advertisements also includes the acceptability of the claim, “prebiotics promote the growth of good Bifidus bacteria to help maintain a healthy digestive system.” Thus, like in Thailand, claims on probiotics and prebiotics are acceptable. Companies can also state that a product “helps to suppress/fight against harmful bacteria in the digestive system, thereby helping to maintain a healthy digestive system.”

Future Expectations

Clearly, ASEAN companies are faced with a challenge if each country in which they are planning to sell their products requires different analysis and/or proof of their claims.

The Codex Alimentarius (prepared jointly by the United Nations and the World Health Organization) and the World Trade Organization, among others, are working toward harmonizing the rules. ASEAN countries have prepared a set of guiding principles for food control systems, which include the Common Guidelines for the Labeling of Prepackaged Foodstuffs.

Another step toward harmonization was taken recently. In early September 2012, the ASEAN countries announced that they have agreed in principle to impose uniform standards in regard to health claims. The objective is to implement these regulations by 2015, but a draft is not yet available.

As these regulations begin to develop, companies in the food industry should approach the relevant government agencies and try to participate in the drafting of the new standards. One of the significant points of discussion will be to ensure the complete harmonization of claims for prebiotics and probiotics products. It is important for the industry to learn the lessons of the EU Regulation and to work closely with regulators to ensure that the harmonized rules have a reasonable degree of continuity with the currently accepted interpretations.

RELATED INSIGHTS​ 

August 29, 2023
Since the June 9, 2022, delisting of all parts of the cannabis plant according to the Narcotics Code, there has been an explosion of cannabis dispensaries operating in Thailand. The Department of Thai Traditional and Alternative Medicine (DTTAM) has issued more than 12,000 cannabis dispensary licenses to businesses in Thailand. A license allows a dispensary to sell cannabis flowers legally. In addition, the DTTAM requests the cooperation of dispensaries in submitting monthly reports about the sourcing, selling, and inventory of cannabis flowers. The DTTAM may suspend the selling license of dispensaries that fail to submit these reports. Apart from the enforcement duties and administrative acts of the DTTAM, the enactment of the laws and regulations pertaining to cannabis seemed to be drastically winding down. One of the reasons was that Thailand had delays in the process of forming a new government following the general election of May 14, 2023. These delays dampened Thailand’s thriving cannabis industry. In particular, the industry has concerns about the uncertainty of the nascent cannabis law. On August 11, 2023, the Narcotics Control Division of the Thai Food and Drug Administration (FDA) posted the Draft Regulation Re: Application for Approval and Approval for Manufacture, Importation, Exportation, Distribution or Possession of Narcotics under Category 5 (Extracts from Cannabis or Hemp Plants Only). This may be the first regulation that the newly formed government implements with regard to cannabis extracts. Unlike the DTTAM’s enforcement activities, the Thai FDA requests that a domestic manufacturer, importer, exporter, or seller of cannabis extracts apply for a license. The Thai FDA, as the authority, will consider granting a license only in the following cases: For medical benefits; For commercial or industrial benefits; For the benefit of medical or scientific analysis or research; and For use by the government for preventing and
July 11, 2023
Enacted in 2009, Indonesia’s current Law on Health (Law No. 36/2009) is due for a refresh. The government realized that the law has not maintained its relevance when it comes to health trends such as digital health, which refers to the provision of health services online (also commonly known as telemedicine). While regulations and policy blueprints, such as Ministry of Health (MOH) Regulation No. 46/2017 concerning National E-Health Strategies, have addressed these shifting trends, Indonesia’s main health legislation has proved inadequate in this regard. For this reason, the government began making plans for an update to the law, and the first draft Omnibus Health Law was published in March 2023. The law addresses digital health and other important issues in today’s health landscape, and it seeks to promote the use of locally made health supplies. The draft Omnibus Health Law represents a notable step forward, but in its attempt to govern and regulate all aspects of health, there are also some issues in the draft that may overlap with some existing government regulations, such as provisions on Halal certification, compulsory licensing of patents, and addictive substances. This article outlines some of the draft law’s key aspects as well as some potential issues. Digital Health In addressing the growing health trend of telemedicine, the draft law confirms, reinforces, and fills gaps left by Indonesia’s three main regulations concerning telemedicine. namely, MOHR No. 20/2019 concerning Telemedicine, MOHR No. 24/2022 concerning Medical Records, and Medical Council Regulation No. 74/2020 concerning Telemedicine (MCR No. 74/2020). One of these regulations, MOH Regulation No. 20/2019, allows health service facilities to provide telemedicine services to other health service facilities. This covers telemedicine services related to radiology, electrocardiography, ultrasonography, and telemedicine consultancy services—including those that reflect developments in science and technology. This is the only regulation concerning
July 10, 2023
One of the more positive outcomes of the COVID-19 pandemic is that telemedicine has become remarkably important as an interactive system between patients and healthcare professionals. Thailand, which ranks near the top as a world medical hub, is a highly favored destination in Asia for expat workers. Currently, the Thai market has both Thai-based and foreign-based platforms with information about healthcare providers and telemedicine readily available. “Doctor Locator,” “Weed Map,” and “Find a Teeth Aligner Dentist” are examples of online platforms connecting patients with medical and telemedicine services. These digital platforms provide information about the location of specialized clinics, cannabis dispensaries, pharmacy stores, and orthodontic practitioners in Thailand. These platforms act as intermediaries between medical care businesses and consumers. As actual medical services are not offered or provided, these digital platforms do not have to be regulated under the Medical Facility Act of Thailand. However, healthcare digital platform services that act as an intermediary or conduit managing information used to connect medical clinics or cannabis dispensaries with patients or customers via a computer network are now regulated under the soon-to-be-implemented Royal Decree on Digital Platforms, regardless of whether payment is actually made via the platform. The regulatory authority for this is the Electronic Transactions Development Agency (ETDA). Under this royal decree, digital platform providers that intend to operate a digital platform service must notify the ETDA prior to initiating operations. The extent of the details to be included in the notification to the ETDA will be more comprehensive if the digital platform: has annual revenue (before expenses) for digital platform services within Thailand exceeding THB 1.8 million (approx. USD 51,200) for an individual operator or THB 50 million (approx. USD 1.42 million) for a corporate or entity operator; or has more than 5,000 users (on average) per month. Apart
July 10, 2023
On June 30, 2023, the Ministry of Health of Vietnam issued Circular No. 14/2023/TT-BYT stipulating the process and procedure for building bidding package prices for procurement of goods and services in the field of medical devices at public health facilities (“Circular 14”). Circular 14 took effect on July 1, 2023, and will be valid through the end of 2023. Circular 14 applies to the procurement of medical devices/equipment and their accessories, spare parts, and supplies, as well as related services of repair, maintenance, inspection, and calibration. Under Circular 14, there are three methods of determining the price of bidding packages: Collecting quotations provided by suppliers of goods and services in the field of medical devices. Surveying the winning bid prices of similar goods and services on the national bidding network system (https://muasamcong.gov.vn). Using the results of price appraisal of a competent state agency that conducts price appraisal, or a specialized price appraisal enterprise. Method (i) must be used first; the two remaining methods can be applied only after method (i) has been unsuccessful. If the investor/procuring entity uses two or more methods to determine the price of bidding packages, it can select the highest price that is suitable to its financial capacity and professional requirements. Circular 14 further sets out the specific step-by-step process to build prices for procuring products and services in the field of medical devices/equipment. Transitional Provision For bidding packages that have already approved a contractor selection plan before July 1, 2023, the approved contractor selection plan will be followed. For bidding packages for which a contractor selection plan has been submitted by the investor/procuring entity but the plan has not yet been approved, the competent person can decide on the approval of the submitted plan or can request the investor/procuring entity to rebuild the bidding